The study compares the effectiveness of yoga practice duration in managing type 2 diabetes (T2D) among the Asian population. Out of 664 results, 22 randomized clinical trials were identified with 1,720 participants, aged 18–65 years, with intervention periods ranging from 5.5 to 24 weeks. Yoga therapies of ≥12 weeks show significant decrease in glycated hemoglobin (HbA1c) levels (Standard Mean Deviation [SMD] = −0.70, p = 0.0001, I2 = 89%), while interventions of <12 weeks did not have statistically significant difference (SMD = −1.04, p = 0.28, I2 = 93%). Weight loss was significant for interventions <12 weeks (SMD = −0.60, p = 0.05, I2 = 0%) but not for those ≥12 weeks (SMD = −0.58, p = 0.17, I2 = 92%). Lipid profile changes varied, with significant reductions in the lipid profile (total cholesterol) (SMD = −0.34, p = 0.05, I2 = 85%) and low-density lipoprotein (LDL; SMD = −0.30, p = 0.05, I2 = 79%) for interventions of ≥12 weeks, while high-density lipoprotein (HDL; SMD = 0.37, p = 0.04, I2 = 85%) increased significantly in this group. Yoga interventions of ≥12 weeks were associated with significant improvements in glycemic control, particularly reductions in HbA1c, along with favorable changes in the lipid profile, among T2D individuals.